Mahoney Stephen F.
SEC CIK 1741389 · EDGAR
BoughtSold
Most active insiders at VRDN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir, 10% | $20.00M | — |
| 2 | Fairmount Healthcare Fund II GP LLC | Dir, 10% | $10.00M | — |
| 3 | Tousignant Jennifer | CLO | — | $419.0K |
| 4 | Harmon Seth | CFO | — | — |
| 5 | Tripuraneni Radhika | Chief Medical Off | — | — |
| 6 | Mahoney Stephen F. | Pres, CEO, Dir | — | — |
| 7 | Beetham Thomas W. | COO | — | — |
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2026-03-09 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Mahoney Stephen F. | Pres, CEO, Dir | F - Tax | $30.19 | -7,408 | 33.3K | -18% | -$223.6K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Mahoney Stephen F. | Pres, CEO | F - Tax | $29.32 | -7,627 | 33.1K | -19% | -$223.6K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Mahoney Stephen F. | Pres, CEO | M - OptEx | — | +18.4K | 40.8K | +82% | — |
| 2024-09-30 | 2024-09-27 | VRDN | Viridian Therapeutics, Inc.\DE | Mahoney Stephen F. | Pres, CEO, Dir | P - Purchase | $23.33 | +21.4K | 21.4K | New | +$499.3K | |
| 2022-12-02 | 2022-11-30 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Mahoney Stephen F. | See Remarks | A - Grant | $0.94 | +3,000 | 17.3K | +21% | +$2,820 | |
| 2021-09-20 | 2021-09-16 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Mahoney Stephen F. | See Remarks | S - Sale | $6.73 | -5,736 | 14.3K | -29% | -$38.6K | |
| 2021-09-16 | 2021-09-14 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Mahoney Stephen F. | See Remarks | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations